Veracyte (NASDAQ:VCYT) Raised to “Strong-Buy” at BidaskClub

Share on StockTwits

Veracyte (NASDAQ:VCYT) was upgraded by equities researchers at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday, BidAskClub reports.

Several other analysts also recently issued reports on VCYT. Needham & Company LLC started coverage on Veracyte in a research report on Tuesday, July 2nd. They issued a “buy” rating and a $33.00 price objective on the stock. Zacks Investment Research downgraded Zynex from a “hold” rating to a “sell” rating in a research report on Saturday, May 4th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $20.06.

VCYT opened at $29.85 on Friday. The business’s fifty day moving average price is $27.18. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.06 and a current ratio of 6.32. The stock has a market capitalization of $1.23 billion, a P/E ratio of -48.15 and a beta of 1.02. Veracyte has a one year low of $8.77 and a one year high of $30.25.

Veracyte (NASDAQ:VCYT) last posted its earnings results on Tuesday, April 30th. The biotechnology company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.05. The company had revenue of $29.53 million for the quarter, compared to the consensus estimate of $28.20 million. Veracyte had a negative return on equity of 23.43% and a negative net margin of 15.51%. Equities analysts anticipate that Veracyte will post -0.28 EPS for the current fiscal year.

In other news, Chairman Bonnie H. Anderson sold 8,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $22.99, for a total value of $183,920.00. Following the sale, the chairman now directly owns 103,292 shares in the company, valued at $2,374,683.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher M. Hall sold 115,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $25.26, for a total value of $2,904,900.00. Following the completion of the sale, the insider now owns 71,462 shares in the company, valued at $1,805,130.12. The disclosure for this sale can be found here. Insiders sold 139,000 shares of company stock worth $3,529,780 over the last 90 days. Company insiders own 8.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gilder Gagnon Howe & Co. LLC purchased a new position in Veracyte during the first quarter worth about $86,400,000. American Century Companies Inc. purchased a new position in Veracyte during the fourth quarter worth about $1,311,000. Squarepoint Ops LLC lifted its position in Veracyte by 8.1% during the fourth quarter. Squarepoint Ops LLC now owns 112,141 shares of the biotechnology company’s stock worth $1,411,000 after buying an additional 8,434 shares during the period. Spark Investment Management LLC lifted its position in Veracyte by 87.2% during the first quarter. Spark Investment Management LLC now owns 323,400 shares of the biotechnology company’s stock worth $8,091,000 after buying an additional 150,600 shares during the period. Finally, California Public Employees Retirement System lifted its position in Veracyte by 6.9% during the fourth quarter. California Public Employees Retirement System now owns 152,124 shares of the biotechnology company’s stock worth $1,914,000 after buying an additional 9,824 shares during the period. Hedge funds and other institutional investors own 94.18% of the company’s stock.

About Veracyte

Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.

Recommended Story: Why is insider trading harmful?

Analyst Recommendations for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Covenant Transportation Group  Downgraded to Sell at BidaskClub
Covenant Transportation Group Downgraded to Sell at BidaskClub
Crown Crafts  Upgraded by ValuEngine to “Sell”
Crown Crafts Upgraded by ValuEngine to “Sell”
Cutera  Rating Increased to Strong-Buy at Zacks Investment Research
Cutera Rating Increased to Strong-Buy at Zacks Investment Research
Cisco Systems  Price Target Cut to $57.00 by Analysts at Citigroup
Cisco Systems Price Target Cut to $57.00 by Analysts at Citigroup
Constellation Pharmaceuticals  Downgraded to “Hold” at Zacks Investment Research
Constellation Pharmaceuticals Downgraded to “Hold” at Zacks Investment Research
Livexlive Media Inc  CEO Purchases $14,602.00 in Stock
Livexlive Media Inc CEO Purchases $14,602.00 in Stock


© 2006-2019 Ticker Report